Andrew Fowell

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Interim Analysis, Metabolic Associated Steatohepatitis, Hepatology +7

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

Eleonora Scorletti, Lokpal Bhatia, Keith McCormick et al. · Hepatology · 2014 · 306 citations

Pathology, Epa Enrichment, Fatty Liver Disease +18

Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease

Eleonora Scorletti, Paul R. Afolabi, Elizabeth A. Miles et al. · Gastroenterology · 2020 · 208 citations · Full text

Dysbiosis, Microbiota, Gut Microbiology +7

Consistent beneficial effects of killer cell immunoglobulin‐like receptor 2DL3 and group 1 human leukocyte antigen‐C following exposure to hepatitis C virus†

Susanne Knapp, U. Warshow, Doha Hegazy et al. · Hepatology · 2009 · 156 citations · Full text